Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - UNIGENE LABORATORIES INCex99-1.htm


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):
December 12, 2012
______________
 
Unigene Laboratories, Inc.
(Exact name of registrant as specified in its charter)
 
Delaware
0-16005
22-2328609
(State or other jurisdiction of
incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
     
81 Fulton Street, Boonton, New Jersey
07005
(Address of principal executive offices)
(Zip Code)
 
(973) 265-1100
(Registrant’s telephone number, including area code)
 
Not Applicable
(Former name or former address, if changed since last report)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
o
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
o
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
o
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 


 
 
 
 
 
Section 8 – Other Events
Item 8.01.  Other Events.
 
On December 12, 2012, Unigene Laboratories, Inc. (the “Company”) a leader in the design, delivery, manufacture and development of peptide-based therapeutics, announced that the results of its successful Phase 2 clinical trial evaluating an experimental oral parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women has been published online by Bone, the Official Journal of the International Bone and Mineral Society. The article will be published in the paper version of the journal in the coming months.
 
A copy of the press release issued by the Company is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
 

Section 9 – Financial Statements and Exhibits

Item 9.01.  Financial Statements and Exhibits.
 
(d)           Exhibits

Exhibit No.
Document Description
99.1
Press Release, dated December 12, 2012

 
 

 
 
Signatures
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
UNIGENE LABORATORIES, INC.
 
     
       
 
By:
/s/ Gregory T. Mayes  
   
Gregory T. Mayes
 
   
President and General Counsel
 
Date:   December 12, 2012 
     
 
 
Exhibit Index

Exhibit No.
Document Description
99.1
Press Release dated December 12, 2012